WASHINGTON / RankWire.AI / – A rare genetic mutation inherited from birth substantially boosts an individual’s overall risk of developing lung cancer—by approximately 25 times, and by roughly 60 times among those who have never smoked, according to a recent publication in the journal Science. The investigation, a collaboration between researchers at the Dana-Farber Cancer Institute and the 23andMe Research Institute, analyzed anonymized genomic data from over 3.3 million individuals. The scientists pinpointed the germline variant, known as EGFR T790M, as one of the most potent inherited factors linked to lung cancer identified to date.
This mutation is situated in the epidermal growth factor receptor gene, which controls cell growth and division within lung tissue. While somatic mutations in EGFR acquired during a person’s life are recognized as key drivers of non-small cell lung cancer, the T790M germline alteration is inherited at birth and found in every cell. Data from the National Cancer Institute indicates that the mutation occurs in roughly 1 in every 15,850 individuals in the United States. Lead author Dr. Jaclyn LoPiccolo highlighted that carrying this variant increases lung cancer risk about 62 times among never-smokers, compared to approximately 11 times for those with a history of smoking.
Genealogical studies revealed that the EGFR T790M mutation is disproportionately prevalent in populations across Tennessee and Alabama’s Southern Appalachian regions. Evolutionary geneticists traced the mutation back to British and Irish settlers who migrated to North America during colonial times. The variant became more common after a population bottleneck around 200 years ago. Senior study author Dr. Pasi A. Jänne stressed that, although lung cancer screening currently focuses mainly on tobacco exposure, recognizing significant genetic risk factors could pave the way for targeted low-dose computed tomography screening in non-smoking carriers.
Dana-Farber’s Research Analyzes Genomes of Over 3.3 Million Individuals
Supported by the National Institutes of Health, the study confirmed through preclinical and clinical trials that the mutation exhibits a strong specific association with lung cancer, without significant links to 17 other common cancers examined within the dataset. Oncologists pointed out that, despite tobacco use remaining the leading cause of lung cancer overall, the increasing occurrence of lung cancer among non-smokers is becoming a significant global health concern. Pharmaceutical companies, including AstraZeneca, continue to develop targeted therapies such as tyrosine kinase inhibitors like Tagrisso to treat EGFR-mutated lung tumors as they progress.
Co-senior author Dr. Alexander Gusev observed that this research demonstrates how a single inherited point mutation can exert an exceptionally strong influence on disease susceptibility. Medical experts advise that individuals with multiple affected family members, unexplained multifocal lung nodules, or ancestral ties to Southern Appalachia seek genetic counseling. Researchers emphasized that possession of the mutation does not guarantee a lung cancer diagnosis, as environmental factors and secondary genetic modifications also influence whether malignancies develop during a person’s lifetime.
EGFR Gene’s Role in Regulating Cell Growth and Division
The research team intends to broaden observational efforts through the ongoing INHERIT Study to examine additional inherited EGFR variants across diverse racial groups. Long-term monitoring aims to identify environmental triggers and secondary genomic changes that determine why some carriers develop tumors while others remain healthy.
More detailed data on population genetics, risk assessment, and screening strategies are available through peer-reviewed medical repositories and institutional release portals. Upcoming international oncology conferences will feature presentations of updated biomarker findings to guide future screening protocols.